These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Role of soluble P-selectin and methylenetetrahydrofolate reductase gene polymorphisms (677C>T) in Egyptian patients with venous thromboembolism.
    Author: Tawfik NM, Deeb ME, Nasr AS.
    Journal: Blood Coagul Fibrinolysis; 2012 Sep; 23(6):537-42. PubMed ID: 22688557.
    Abstract:
    Venous thromboembolism (VTE) is a significant problem for surgical and medical hospitalized patients, leading to the possibility of serious illness and risk of death. The aim of the present study was to investigate soluble P-selectin levels and genetic polymorphisms in 5, 10-methylenetetrahydrofolate reductase (MTHFR 677C/T) and to evaluate its associations with VTE was the aim of work. The study involved 49 patients diagnosed as having VTE (as a patients group) as well as 24 apparently healthy volunteers (as controls group). All the participants included in the study were assessed for soluble serum P-selectin levels using the enzyme-linked immunosorbant assay technique. All the participants included in the study were genotyped for detection of MTHFR gene polymorphisms (677C > T) by restriction fragment length polymorphism. Concerning the results of soluble P-selectin, there were statistically significant differences between the two groups (P = 0.0210). Concerning the results of MTHFR gene polymorphisms, there were no statistically significant differences between the two groups regarding CT allele (P = 0.8790), but there were highly statistically significant differences between the two groups regarding CC, TT alleles as well as CC/CT and TT/CT alleles (P < 0.0001). According to our study, elevated soluble P-selectin levels as well as MTHFR gene polymorphisms are to be considered as independent risk factors for development of VTE, so it may be recommended to include P-selectin assay and detection of MTHFR gene polymorphisms when considering patients with thromboembolism even in the absence of any other predisposing factors.
    [Abstract] [Full Text] [Related] [New Search]